NCT07003451Not yet recruiting
Novel Biomarkers in Assessment of Interstitial Lung Disease Associated With Rheumatoid Arthritis Patients
Source: ClinicalTrials.gov · Last updated 28 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
\- Assess Krebs von den Lungen-6 (KL-6) and Calprotectin as novel biomarkers for diagnosis of ILD among Rheumatoid arthritis patients
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 26 May 2025
- Start date
- 1 Oct 2025
- Primary completion date
- 1 Jan 2026
- Lead sponsor
- Assiut University
- Diseases
- Rheumatoid arthritis
- NCT number
- NCT07003451
What you commit to
- Study type: Observational
- Planned participants: 60
- From 1 Oct 2025 to the primary completion date, 1 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with evidence of worsening or exacerbation of RA over the previous 6 months,
- concomitant diagnosis of an active neoplasia, or
- patients who had previously received radiotherapy,
Other illness
- End organ failure.
Other
- Patients who refuse to participate in the study,
Who the study is looking for
- Confirmed diagnosis of Rheumatoid arthritis, age \> 18 years.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Assiut University hospital Coordinator of this site? Confirm its status | Asyut | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.